FOLH1 and prostate cancer: These radiotracers rely on the high expression of PSMA in the majority of prostate cancer cells, especially in the late stages of the disease, providing an improved diagnosis and monitoring of therapeutic response in comparison with the other available diagnostic and therapeutic options.